No Data
No Data
Avidity Biosciences to Present Preliminary Data From Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living With Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDEAvidity to host Vo
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Avidity Biosciences(RNA.US) Director Sells US$149.48K in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of common stock on May 20, 2024 at an average price of $29.8962 for a total value of $149.48K.Source: Announcement What is state
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Poised for Growth: Buy Rating Affirmed Amidst Encouraging Competitive Landscape
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna